ACTRN12609000790246已完成1 期
Phase I study of the maximum dose tolerability of carboplatin-irinotecan-paclitaxel combination (CIP) in patients with advanced refractory solid tumours
Hellenic Cooperative Oncology Group0 个研究点目标入组 20 人开始时间: 2009年9月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •Performance status: World Health Organization (WHO) 2 Life expectancy: At least 3 months Hematopoietic: Platelet count at least 100,000/mm3 Absolute neutrophil count at least 3,000/mm3 Absolute lymphocyte count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Transaminase no greater than 2.5 times upper limit of normal Renal: Creatinine no greater than 1.4 mg/d
排除标准
- •Cardiovascular: myocardial infarction within 6 months. Current, uncontrolled cardiac arrhythmias. History of anaphylactic reactions. Pregnancy. Serious uncontrolled, concurrent medical disorders.
研究者
相似试验
Enrolling By Invitation
1 期
Engineered T cells for the treatment of B-cell leukemiaB-cell leukemiaCAR-CD19 T cellTCTR20160921001TCELS15
Enrolling By Invitation
1 期
K cells for the treatment of neuroblastomaHigh risk neuroblastomaNK cellNeuroblastomaTCTR20160918001TCELS15
进行中（未招募）
1 期
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a plasma cell tumor.Multiple myeloma in early relapse after intensive front line therapyMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2018-001741-14-ITOSPEDALE SAN RAFFAELE3
进行中（未招募）
1 期
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a malignant neoplasm of the central nervous systemGlioblastoma MultiformeEUCTR2018-001404-11-ITGENENTA SCIENCE SR21
尚未招募
不适用
GEN-001 multiple dose phase 1 studyKCT0006311Jeonbuk National University Hospital12